TPTX's logo.
Ticker Symbol: TPTX

Turning Point Therapeutics Inc

$44.41 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001595893

Company Profile

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags:
  • Biotechnology
  • Pharmaceuticals: Major
  • Health Technology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: - ( 0.00%)
Days Range: $75.98 - $76.01
Beta: -
52wk. High: -
52wk. Low: -
Ytd. Change 0.00%
50 Day Moving Average: -
200 Day Moving Average: -
Shares Outstanding: 50074277

Valuation

Market Cap: 380.6B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A